

TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES)

Madrid, 16 November 2021

In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, Laboratorios Farmacéuticos ROVI, S.A. (hereon, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Securities Market Commission the following

OTHER RELEVANT INFORMATION

In accordance with rule 4, section 2 c) of Circular 1/2017, of 26 April 2017, of the Spanish National Securities Market Commission, on liquidity agreements ("**Circular 1/2017**"), ROVI communicates that the liquidity agreement signed with Renta 4 Banco, S.A. effective as from 8 May 2019 (the "**Liquidity Agreement**"), the transactions of which were suspended on 3 November 2021, has been terminated with effects as of today.

The reason for termination is the commencement of a share buyback program under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse ("**Regulation 596/2014**") and its implementing regulations, as was communicated by the Company on 3 November 2021 by means of a communication of inside information (registry number 1143).

Pursuant to rule 4, section 2 b) of Circular 1/2017, below is a description of the development of the Liquidity Agreement including the transactions carried out thereunder, both in aggregate since its effective date and also in relation to the transactions carried out during the fourth quarter of 2021 until termination (from 1 October 2021 to 16 November 2021).

Aggregate information since the effective date of Liquidity Agreement:

- Shares' account at signing of agreement: 25,000 shares.
- **Cash account at signing of agreement**: 457,500.00 euros.
- Total purchases: 2,212,921 shares.
- Cash corresponding to total purchases: 82,893,238.50 euros.
- Average price of total purchases: 37.4587 euros.
- Total sales: 2,231,216 shares.
- Cash corresponding to total sales: 83,272,789.45 euros.

- Average price of total sales: 37.3217 euros.
- Shares contributions: 8,092 shares.
- Cash contributions: 338,667.47 euros.
- Final shares' account on 16 November 2021: 14,797 shares.
- Final cash account on 16 November 2021: 1,130,412.65 euros.

Information from 1 October 2021:

- Shares' account on 1 October 2021: 11,554 shares.
- Cash account on 1 October 2021: 510,434.14 euros.
- Purchases carried out since 1 October 2021: 93,570 shares.
- Sales carried out since 1 October 2021: 98,419 shares.
- Average price of purchases carried out since 1 October 2021: 57.1241 euros.
- Average price of sales carried out since 1 October 2021: 57.1942 euros.
- Cash corresponding to total purchases carried out since 1 October 2021: 5,345,104.80 euros.
- Cash corresponding to total sales carried out since 1 October 2021: 5,628,991.60 euros.
- Final shares' account on 16 November 2021: 14,797 shares.
- Final cash account on 16 November 2021: 1,130,412.65 euros.

The transactions carried out under said agreement during the fourth quarter of 2021 until its termination (from 1 October 2021 to 16 November 2021) are as follows:

Date of transaction	Purchase /Sale	Number of shares	Block	Number of transactions	Average price (€)	Cash (€)	Position to date (shares)	Net value
01/10/2021	Purchase	3.373	NO	16	56,4876	- 190.532,70	14.927	319.901,44
01/10/2021	Sale	1.650	NO	10	57,0057	94.059,40	13.277	413.960,84
04/10/2021	Purchase	3.175	NO	9	55,1087	- 174.970,00	16.452	238.990,84
04/10/2021	Sale	2.120	NO	11	55,4104	117.470,00	14.332	356.460,84
05/10/2021	Purchase	1.707	NO	7	54,7172	- 93.402,20	16.039	263.058,64
05/10/2021	Sale	1.723	NO	15	55,0913	94.922,30	14.316	357.980,94

Date of transaction	Purchase /Sale	Number of shares	Block	Number of transactions	Average price (€)	Cash (€)	Position to date (shares)	Net value
06/10/2021	Purchase	3.000	NO	11	54,2000	- 162.600,00	17.316	195.380,94
06/10/2021	Sale	4.223	NO	19	54,3264	229.420,30	13.093	424.801,24
07/10/2021	Purchase	5.215	NO	26	54,0213	- 281.721,10	18.308	143.080,14
07/10/2021	Sale	5.360	NO	19	54,0884	289.914,00	12.948	432.994,14
08/10/2021	Purchase	6.697	NO	30	53,9678	- 361.422,60	19.645	71.571,54
08/10/2021	Sale	6.374	NO	25	54,0187	344.315,10	13.271	415.886,64
11/10/2021	Purchase	5.632	NO	19	53,9390	- 303.784,70	18.903	112.101,94
11/10/2021	Sale	5.587	NO	41	53,9956	301.673,40	13.316	413.775,34
12/10/2021	Purchase	2.720	NO	13	54,3958	- 147.956,60	16.036	265.818,74
12/10/2021	Sale	3.997	NO	24	54,2504	216.839,00	12.039	482.657,74
13/10/2021	Purchase	2.678	NO	19	55,5058	- 148.644,60	14.717	334.013,14
13/10/2021	Sale	4.042	NO	26	55,4072	223.956,10	10.675	557.969,24
14/10/2021	Purchase	4.716	NO	29	56,4151	- 266.053,50	15.391	291.915,74
14/10/2021	Sale	4.716	NO	25	56,5003	266.455,60	10.675	558.371,34
15/10/2021	Purchase	4.600	NO	29	56,3598	- 259.255,10	15.275	299.116,24
15/10/2021	Sale	5.400	NO	35	56,3711	304.403,90	9.875	603.520,14
18/10/2021	Purchase	2.900	NO	20	56,1684	- 162.888,40	12.775	440.631,74
18/10/2021	Sale	2.719	NO	20	56,1850	152.767,10	10.056	593.398,84
19/10/2021	Purchase	4.876	NO	29	56,5993	- 275.978,20	14.932	317.420,64
19/10/2021	Sale	4.624	NO	28	56,6589	261.990,80	10.308	579.411,44
20/10/2021	Purchase	1.232	NO	6	57,6494	- 71.024,00	11.540	508.387,44
20/10/2021	Sale	2.734	NO	15	57,4864	157.167,80	8.806	665.555,24
21/10/2021	Purchase	4.601	NO	31	57,4631	- 264.387,60	13.407	401.167,64
21/10/2021	Sale	4.549	NO	40	57,5366	261.734,00	8.858	662.901,64

Date of transaction	Purchase /Sale	Number of shares	Block	Number of transactions	Average price (€)	Cash (€)	Position to date (shares)	Net value
22/10/2021	Purchase	4.178	NO	39	60,0113	- 250.727,20	13.036	412.174,44
22/10/2021	Sale	5.071	NO	44	59,9615	304.064,90	7.965	716.239,34
25/10/2021	Purchase	4.650	NO	35	59,2266	- 275.403,60	12.615	440.835,74
25/10/2021	Sale	4.950	NO	47	59,2076	293.077,50	7.665	733.913,24
26/10/2021	Purchase	4.450	NO	27	59,7697	- 265.975,00	12.115	467.938,24
26/10/2021	Sale	5.100	NO	33	59,8607	305.289,60	7.015	773.227,84
27/10/2021	Purchase	5.252	NO	33	59,6295	- 313.174,20	12.267	460.053,64
27/10/2021	Sale	4.198	NO	49	59,6223	250.294,40	8.069	710.348,04
28/10/2021	Purchase	5.884	NO	31	59,1216	- 347.871,30	13.953	362.476,74
28/10/2021	Sale	3.516	NO	25	59,2026	208.156,50	10.437	570.633,24
29/10/2021	Purchase	2.836	NO	11	59,0409	- 167.440,00	13.273	403.193,24
29/10/2021	Sale	6.564	NO	44	59,4598	390.293,80	6.709	793.487,04
01/11/2021	Purchase	4.719	NO	18	61,1657	- 288.641,10	11.428	504.845,94
01/11/2021	Sale	4.481	NO	20	61,3186	274.768,60	6.947	779.614,54
02/11/2021	Purchase	4.479	NO	37	60,5606	- 271.251,10	11.426	508.363,44
02/11/2021	Sale	4.721	NO	53	60,5714	285.957,50	6.705	794.320,94
Contributions							8,092	338,667.47
Charges								-2,575.76
TOTAL		-4,849				283,886.80	14,797	1,130,412.65

Mr Juan López-Belmonte Encina Chairman and Chief Executive Officer Laboratorios Farmacéuticos ROVI, S.A.